Thread by @Biotech2k1

1/ Bargain Hunting in #Genomics:

These are the companies that rank in my top picks for people to use as a jumping off point to do their own research.

2/ My top pick here is clearly $BEAM. I think they got the best management and science. I know it is still a very expensive company at $4.5 billion market cap and not even any human data yet. It should probably be worth more like $3 billion.

3/ I do think they have the best long term potential with their wholly owned programs and a long list of partnerships.

4/ $NTLA comes in as my 2nd pick in this space. It is another gene editing company. They have promising early data in their first indication. They have a new management that seems very strong. They have a lot of vision around where the science is going.

5/ This is another very expensive company even after the massive crash of the biotech sector. There is still a huge level of hope in these early editing programs. I think they should be closer to $5 billion market cap based on their very early stage of development.

6/ $CRSP comes in at 3rd. They are another gene editing company mainly focused on ex-vivo cell editing with CRISPR. They are the most advance clinically and have the best data.

7/ The company looks very cheap down here, but I think they might have lost some of that vision and inspiration. It has been the exact same pipeline for years with no new programs to keep up with the ever evolving landscape.

8/ They come is as 3rd as I worry they lost that ambition and could be falling behind the other companies like $BEAM and $NTLA.

9/ $NVTA comes in 4th. They have the potential to be one of the biggest opportunities in genetic testing and personalized medicine. They have been spending heavily to build out this business. This leaves many worried about that massive cash burn.

10/ That is why they are ranked down here. They still have a lot to prove to the market and to me. I think they could be a huge opportunity, but now they have to show us the money.

11/ The stock is insanely cheap if they can get the execution down and drive margins and the bottom line. I think this year will be a make or break for them to show the market they can do what they claim they can do.

12/ $PACB comes in 5th place. They are my only sequencing company. They are in a very competitive space. I think the company offers great value here, but they could be losing market share to competitors.

13/ They have seen weakness over the past 2 quarters and their guidance for 2022 was light. We have to know if this is more of a sector issue due to Covid or if they are losing business to competitors.

14/ If it turns out to be just general sector weakness, then this will be a great value to buy. The problem is we have to wait until we know if this is company specific or the entire space.